In situ hybridization is a technique used in the lab to locate a DNA or RNA sequence in biological material. A biological sample from an individual, such as tissue sections, cells, or chromosomes, is attached to a glass slide and then subjected to a "probe," which is a little bit of single-stranded DNA labeled with a chemical or fluorescent dye. The labeled probe locates and attaches to the biological sample's matching sequence. A microscope can then be used to see where the bound probe is located.
The identification of individual messenger ribonucleic acid
(mRNA) molecules is one of the most common uses of ISH. ISH provides for the
exact localization of a peptide synthesis site, and ISH paired with
immunocytochemistry (ICC) allows for the differentiation of a biosynthesis site
(ISH and ICC positive) from storage or uptake sites (ICC positive only). The
study of the functional condition of cells is a second key application. Changes
in gene expression can be semi quantified in diseased settings or after
physiological or pharmacological treatments. It is also possible to conduct
developmental studies on the onset of gene expression and control.
The tools category dominated the in situ hybridization market in 2020, accounting for 36.3 percent of total revenue. The growing number of diagnostic and research facilities is driving up demand for devices. In addition, the expansion of in situ hybridization is expected to be boosted by an increase in the number of strategic activities among competitors to expand their product portfolio.
The ISH market's growth is being fueled by low-cost technical
advancements. For example, in May 2021, a group of researchers published a
report claiming that using chromogen-based RNA in situ hybridization to detect
druggable cytokines in atopic dermatitis and psoriasis is an efficient way.
Technological progress broadens the scope of in-situ hybridization and propels
segment expansion.